Latest posts tagged with #LiverTwitter on Bluesky
📌 First meta-analysis on recompensation in decompensated cirrhosis
🔍 More common in viral etiologies & lower MELD
📉 Linked to lower risk of HCC & death
✅ A meaningful clinical endpoint
Read more here: https://ow.ly/tYnJ50YvNUo
#LiverTwitter @wong__yujun @BavenoCoop
📊 CHB patients on Peg-IFN:
✅ HBsAg decline at wk24 & baseline HBsAg best predict functional cure.
✅ HBV RNA & HBeAg levels (wk12/24) best predict HBeAg loss.
Guiding personalized therapy.
👥 @HenryEChang@asianliverctr
#Hepatology #HBV #LiverTwitter
👉 www.xiahepublishing.com/2310-8819/JC...
Predicting PEG-IFN response in hepatitis B: HBsAg decline at week 24 best predicts functional cure. For HBeAg loss, HBV RNA & HBeAg levels at week 12 are key. Better markers = tailored therapy. #HBV #HepatitisB #LiverTwitter
New expert consensus on inherited hyperbilirubinemia (Gilbert, Crigler-Najjar, etc.) now available. Led by Chinese Medical Association, it integrates latest advances to guide diagnosis & management. #LiverTwitter #Genetics #MedTwitter
👉https://xiahepublishing.com/2310-8819/JCTH-2025-00440
🚨Just 3 weeks away‼️
Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷
🗓️ Dec 4–5 @ CNAM
💳 Onsite €150 | 💻 Online FREE
👉 Organized by EURO-VALDIG NET & FILFOIE
🔗 Registration → app.evalandgo.com/f/325218/4qE...
📘 Updated program below 👇
#LiverTwitter
So excited to be in Washington DC for my first #TLM25 with wonderful colleagues!
A toast to you all with a delicious mocktail! Will see you around! Can’t wait!
#LiverTwitter @aasldnews.bsky.social
🚨Just one month away‼️
Join the VALDIG PSVD Meeting 2025 in Paris 🇫🇷
🗓️ Dec 4–5 @ CNAM
💳 Onsite €150 | 💻 Online FREE
👉 Organized by EURO-VALDIG NET & FILFOIE
🔗 Registration -> app.evalandgo.com/f/325218/4qE...
📘 Full program below 👇 #LiverTwitter
Important Deadlines for #BavenoVIII ‼️
💶 Early registration: 15 Dec 2025
🪶 Abstract submission: 15 Jan 2026
📄 Satellite programmes & speakers: 15 Jan 2026
📦 Sponsor material delivery at venue: 20 Mar 2026
Stay tuned for updates -> 🔗 baveno8.org
#LiverTwitter
💬 Proud to be featured by #CORDIS! They spotlight #TherVacB's clinical trial as a key step toward a functional cure for chronic #hepB.
🎥 Our awareness videos with @dsolve.bsky.social explain diagnosis, co-infection & care.
🔗 link.europa.eu/QMFx3J
#HBV #HDV #LiverSky #HepSky #LiverTwitter
Join us in VALENCIA for the 3rd International Workshop on LIVER and GUT FIBROSIS, 16-17 Oct. Registration closes 6th Oct
eventos.adeit.es/go/3rdFibros... #LiverGutFibrosis25 #livertwitter #IBD #fibrosis @ciberisciii.bsky.social @myueg.bsky.social @ibddoctor.bsky.social @crohnscolitisfdn.bsky.social
The FDA accepted Echosense’ Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography (FibroScan) as a reasonably likely surrogate endpoint in clinical trials for MASH.
Learn more: www.hcplive.com/view...
#LiverTwitter
Register now for this specialist workshop on LIVER and GUT FIBROSIS, taking place on 16-17 Oct, in the beautiful city of VALENCIA. Check out the programme here: eventos.adeit.es/130936/secti... #fibrosisvlc #LiverGutFibrosis25 #livertwitter #IBD
Semaglutide 2.4 mg has received approval for MASH.
In April, #DiabetesDialogue recorded a special edition episode on the ESSENCE trial with Dr. Arun Sanyal.
www.hcplive.com/view/diabete...
#Hepatology #LiverTwitter
Send your abstract in before 31st August! Travel grants -courtesy of PharmaNestInc - will be awarded to stand out submissions eventos.adeit.es/go/3rdFibrosis #fibrosisvlc #LiverGutFibrosis25 #livertwitter #IBD @ciberisciii.bsky.social l
@timjobson.bsky.social joined the Surfing the MASH Tsunami podcast with Roger Green & Louise Campbell to discuss hepatoSIGHT™ and how it’s speeding better treatments to patients. A must-listen for #ClinicalTrials & #LiverDisease #LiverTwitter
podcasts.apple.com/gb/podcast/6...
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis: results from the phase 2, randomised MIRNA study
www.thelancet.com/journals/lan...
#LiverTwitter #MedTwitter
Your input matters! Now through August 11, #AASLD is accepting public comments for the proposed recommendations in the AASLD Practice Guideline on Adult #LiverTransplantation: Candidate Evaluation. Submit your comments today! bit.ly/4o7MkCx #LiverTwitter
Protons, Photons, & everything in between. Join us on July 15th as we breakdown NRG-GI003 comparing protons & photons for hepatocellular carcinoma with study PI, Dr. Ted Hong. Listen to older episodes and find where to follow at nrgoncology.org/Podcast #LiverTwitter #LiverX #HCC
Creation of a new VA liver transplantation center increased access and retained care within veterans health administration
Read the brief report 👇🏼
#livertwitter
#liversky
@aasldnews.bsky.social
@livertransplant.bsky.social
journals.lww.com/lt/citation/...
Successful #HCV treatment with DAAs is associated with a reduced risk of several extrahepatic manifestations, including chronic kidney disease, stroke, major adverse cardiac events, and neurocognitive disorders.
Learn more: www.hcplive.com/view...
#LiverTwitter
Excited to see what BlueSky can offer in the #LiverTwitter field.
I hope to join the discussion on #WilsonDisease and share our results here going forward.
🏆 Community Award to @docberza.bsky.social (Bern, Switzerland) at #EASL2025
💬 Beautiful and emotional intro by @RodriguesSu24
🙏 So proud to have you in @bavenocoop.bsky.social
— well deserved!
#LiverTwitter
🔗 Full paper: doi.org/10.1111/apt....
📝 Editorial by @reibergerthomas.bsky.social and Benedikt Simbrunner:
onlinelibrary.wiley.com/doi/epdf/10....
#LiverTwitter
Engage with our panellists and ask your burning questions about CCA diagnostic tests. Join the conversation on our virtual platform: rb.gy/s6p2aw
#AMMF2025 #Livertwitter #cholangiocarcinoma
Exhibitor booths are not usually meeting highlights but this is an exception. Kudos to @boehringerglobal.bsky.social
on this artistic rendition on the theme of liver health and disease @easlnews.bsky.social #EASLCongress
#livertwitter
#LIVERAIM networking session has started at track hub8!
Join us and learn how #biomarkers of #liverfibrosis can reshape the future of Hepatology
#livertwitter #EASLCongress @aleksanderkrag.bsky.social @ihieurope.bsky.social @salvatore-piano.bsky.social @easlnews.bsky.social @IHI
